SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited ...

CARVYKTI ® net trade sales of approximately $334 million and $963 million for the fourth quarter and full ... Centered in the US, Legend is building an end-to-end cell therapy company by ...

A mouth-watering quarter-final line-up will be finalised ... The reds are well spread for a big break here, one that would end Murphy’s challenge once and for all. Murphy rattles off another ...

Callan Ward has added to his legend after what shapes as a career-ending knee injury as GWS roared back to beat Richmond by ...

With 1:32 left in the fourth quarter ... But I know in the end, she’s always doing what she thinks she needs to do for us to win.” That’s why she’s a legend. Because she has the audacity ...

(Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited financial results and key corporate highlights. “CARVYKTI, underpinned by its continued strong ...

We use Adjusted Net Loss and Adjusted Net Loss per Share (which we sometimes refer to as “Adjusted EPS” “ANL per Share”) as performance metrics. Adjusted Net Loss and ANL per share are not ...